{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"The majority of patients were deemed not to have primary mucinous ovarian cancer post hoc. The trial accrued slowly and was stopped early."},"pointOfContact":{"email":"lgedeon@gogstats.org","organization":"NRG Oncology","phone":"716-845-1169","title":"Linda Gedeon on behalf of William Brady, PhD"}}